Journal
THERAPEUTIC DRUG MONITORING
Volume 30, Issue 3, Pages 333-340Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FTD.0b013e31816e2d4b
Keywords
oxycodone; metabolites; liquid chromatography mass spectrometry; therapeutic drug monitoring
Ask authors/readers for more resources
A sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of oxycodone, noroxycodone, oxymorphone, and noroxymorphone. Following solid-phase extraction, the analytes were separated oil a reverse-phase, column by gradient elution and analyzed by MS/MS. The analytes were found to be stable in plasma for at least three freeze-thaw cycles and 5 hours at room temperature, and also in the reconstitution solution at 8 degrees C for at least 48 hours. The lower limits of quantification were 0.1 ng/mL for oxycodone and oxymorphone and 0.25 ng/mL for noroxycodone and noroxymorphone. All calibration curves were linear up to 100 ng/mL. The extraction recoveries were more than 85%, the intraday and interday coefficients of variation were < 15%, and the accuracy was > 90% for all analytes at relevant plasma concentrations. The method has been used in the therapeutic drug monitoring of more than 1000 clinical plasma samples. About 50 concomitantly used drugs were tested for possible ion suppression and found not to interfere with the method. In conclusion, this method is suitable for pharmacokinetic studies in patients and healthy volunteers, and it can be applied to therapeutic monitoring of oxycodone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available